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include = > 1 cohorts, retrospective or prospective data collection, disease or treat-
ment-based inclusion criteria, various outcomes (safety, prescription pattern or 
off-label use, comparative effectiveness, quality of life or other patient-reported 
outcomes[PRO], health economics, or other objectives), site/investigator selection 
(in-house, commercial, professional organization, or government databases), and 
country-specific requirements. Methods: Studies that used integrated and non-
integrated DM systems were evaluated to identify criteria for use and associated 
protocol template language (PTL), including required, preferred, or optional text 
based on various study designs and objectives. Results: Multiple DM systems were 
evaluated and algorithms created with use criteria. For integrated DM systems that 
combined data capture and trial management, simplified PTL was identified. DM 
PTL was adjusted to include paper or electronic data capture (EDC) methods, paper/
electronic-based PROs, paper/electronic case report forms (CRFs), data (eg. subject/
physician entered, site or aggregate, medical or laboratory records) and appropriate 
subject data protection. For non-integrated systems that required separate DM and 
trial management, additional PTL was identified for these complex DM systems. The 
templates denoted minimum required language and suggested extended language 
for more elaborate designs. To support the numerous NIS study design types, we 
included decision trees to account for various study goals, associated outcomes, 
and data collection requirement. Our data collection decision tree summarized the 
variety of potential study designs with frequently used study goals/outcomes and 
associated data collection techniques. ConClusions: Integrated DM systems pro-
vided the most flexibility and simplicity of protocol template language. All template 
language was created as adjustable to meet the typical study designs encountered 
in PASS studies. This additional information was to support the protocol devel-
opment team in creating the final protocol in a timely manner and in reviewing 
client-provided templates.
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objeCtives: Conducting real world evidence (RWE) research on patients with rare 
diseases is particularly challenging when using only one type of data (e.g. insur-
ance claims). Myelofibrosis (MF) is a rare, hematological cancer with global annual 
incidence rate of < 1 - 2.4 cases per 100,000 patients. MF is characterized by the 
reduced ability of bone marrow to synthesize blood cells which can result in anemia, 
thrombocytopenia, and higher risk of infection. Absent adequate, recent data on MF 
patients, a practice-based network (PBN) data platform was developed to facilitate 
RWE research on MF patients. Methods: MF patients observed in IMS Health data-
bases between November 2010 to October 2012 were identified. Academic centers of 
excellence and large community oncology practices treating MF patients were then 
identified to link additional patients into the platform using a HIPAA-compliant 
patient de-identification algorithm. Patient demographics and attributes of dis-
pensed prescriptions, private practitioner visits, and electronic medical record data 
including laboratory information were collected across patients from January 2000 
to March 2013. Descriptive analyses of demographic and clinical characteristics were 
conducted to assess the generalizability of the sample versus literature. Results: 
A total of 6362 U.S. MF patients were identified in the platform. Mean (SD) age was 
67 (12.6) and 45% of patients were female. Mean (SD) Charlson Comorbidity Index 
was 4.36 (2.4). Among the subset of 529 patients with laboratory results, 63% were 
identified as anemic and 34% had platelet counts 50,000 - 100,000 / microL. All U.S. 
geographic regions were represented. ConClusions: Demographic and clinical 
results suggest that this large sample of MF patients is comparable to prior esti-
mates of the broader MF population. This case study of U.S. MF patients suggests it 
is important to look beyond any one data source and to build PBN platforms with 
key clinical domains spanning multiple geographic regions when conducting RWE 
research on patients with rare diseases.
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objeCtives: Observational studies are often planned on an ad hoc basis, with 
the risk that methods are inconsistent and that aims overlap rather than comple-
ment each other. Our objective was to develop a systematic approach for identify-
ing observational data sources for an integrated global programme of real-world 
evidence gathering, to support an important new indication for an antiplatelet 
drug. Methods: Systematic literature and Web searches, supplemented with email 
and telephone contact with data owners, were used to identify and characterize 
registries and health care databases suitable for use in observational studies of 
myocardial infarction and acute coronary syndromes. The ability to identify patients 
across data sources was also assessed. Data were captured and evaluation criteria 
applied, including compatibility with aspects of an ongoing randomized clinical 
trial (patient population, treatments, outcomes, and length of follow-up [≥ 3 years]). 
Selection criteria included accessibility; availability of inpatient, outpatient, cardiac 
event, and drug data; and generalizability. Results: Over 2700 publications were 
screened; we identified 216 registries and 380 databases (primarily of administra-
tive claims and electronic medical records). Of these, 12 registries, and 21 databases 
met the evaluation criteria and were assessed in depth. After application of the 
selection criteria, 5 registries and 12 databases were recommended. Recommended 
data sources ranged in size, each capturing data on between 4000 and 11 million 
the user’s behavior upon navigating the site. Results: Since the site began to get 
monitored on July 1, 2012 and up until June 25, 2013, 19.738 hits were registered, with 
a monthly average of 1.661 hits. More than 65 countries accessed the site, the major-
ity coming from the USA, UK and Portugal. Brazil leads with 93%. The rate of return 
of people who frequently accessed the site was 24,7%. Upon navigating the site, 
more than 45.000 visualizations of the web page were registered. ConClusions: 
This monitoring began in 2012 and therefore no previous years exist to serve as a 
basis for comparison. The results show that a considerable number of users have 
access to the site and consequently know about REBRATS. From the perspective of 
the website, the number of hits is still low, however, considering that the HTA field 
is a recent one in Brazil, its growth has been gradual. On an international level, 
new dissemination strategies are necessary in order to create greater visibility and 
promotion of the network.
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objeCtives: Identifying treatment pathways based on administrative data or elec-
tronic medical records is generally a complex task, as many incidental events may 
hide the key trends. The purpose of this study was to propose a transparent method-
ology for defining treatment pathways using a large longitudinal real life database. 
The application of two alternative algorithms with different variants in Parkinson’s 
disease (PD) was described. Methods: In the first method, a new treatment line 
was assumed to start when a pre-specified number of consecutive prescriptions of 
drugs from the same PD drug class or combination of classes (rasagiline, selegiline, 
dopa agonists, COMT inhibitors, levodopa and derivatives) occurred. In the second 
method, start and end dates of continuous treatment periods (i.e. without gaps 
higher than six months between prescriptions) were determined for each drug class 
independently of each other. Combinations were assumed to be used when differ-
ent treatment periods overlapped. Algorithms were tested using medical records 
of patients with Parkinson’s disease (PD) extracted from the UK Clinical Practice 
Research Datalink (CPRD). The outputs of the different algorithms were described 
in details for ten patients, randomly selected. The sensitivity of the algorithms to 
changes in assumptions was tested. Results: The first algorithm did not systemat-
ically capture the addition of a new drug to the current treatment as combined drugs 
were not necessarily prescribed or renewed during the same consultations. However, 
the second method well captured the treatment lines observed but sometimes cre-
ated undue treatment lines from isolated prescriptions. This issue was overcome 
by deleting short lines lasting less than three months. ConClusions: The second 
algorithm developed in this study provided an accurate description of the treatment 
strategies developed by prescribers in Parkinson’s disease in the UK using a limited 
number of assumptions and may be useful for other chronic diseases.
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objeCtives: To identify and assess real world data sources for observational 
research on lymphoma and multiple myeloma (myeloma) in Europe. Methods: 
Structured (EMBASE and MedLine) and grey literature searches were conducted 
to identify relevant European data sources. Identified data sources were screened 
based on the following criteria: inclusion of patient-level data and patients with 
NHL, HL, or MM diagnoses, possession of data dictionaries, and ongoing data accrual. 
Where regional registries were proven to feed data into national registries, only 
the national data source was retained for evaluation. Data sources passing initial 
screening were subjected to further evaluation based on publicly reported infor-
mation, questionnaires and / or interviews with data source owners, and informed 
by lymphoma and myeloma treatment pathway analysis. Results: One hundred 
eighty-six data sources from 21 countries were identified; of which cancer regis-
tries (R) accounted for 65%. The remaining 35% non-registry (NR) sources included 
biobanks, clinical audits, data linkage initiatives, drug databases and electronic 
medical records. Screening removed 101 sources. Of the 85 sources retained after 
screening, roughly half (52%) were NR sources and a majority (74%) were from six 
countries: France, Germany, Spain, Sweden, The Netherlands, and The UK. NR data 
sources generally collected more data attributes than R data sources. These data 
attributes included symptoms (collected by 52% NR, and 21% R data sources), treat-
ment regimens (81% NR, 40% R), and resource use (49% NR, 8% R). ConClusions: 
Compared with disease registries, non-registry data sources in Europe typically have 
more diverse data attributes and are therefore potentially better for lymphoma and 
myeloma research. This result may guide the selection of data sources for observa-
tional research. As scrutiny of real-world outcomes for reimbursement of oncology 
drugs increases, much work remains to be done to increase the visibility and utility 
of data sources for health care payers and providers.
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objeCtives: To address non-interventional study (NIS) protocol DM and data 
collection requirements in PASS observational study designs. These studies may 
